A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy.

Authors

Ugo De Giorgi

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Ugo De Giorgi , Eleni Efstathiou , William R. Berry , Heather Ann Payne , Katarzyna Madziarska , Katharina Modelska , Xiaowei Guan , Jennifer Sugg , Joyce Leta Steinberg , Cora N. Sternberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 Genitourinary Cancers Symposium

bookmark_border

Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).

First Author: Tomasz M. Beer

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures.

First Author: Stephen J. Freedland

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.

First Author: Jeffrey Lee Jensen

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).

First Author: Neeraj Agarwal